Spherix Announces Third Quarter 2012 Financial Results
BETHESDA, Md., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the three and nine months ended September 30, 2012.
On November 13, 2012, the Company expanded its Board of Directors to eight board members and will be re-examining its business strategies and exploring strategic alternatives. This effort may result in the divestiture or winding down of certain of our current businesses and the possible entry into a new, as yet unidentified business, including acquisitions.
Financial Results for the Three and Nine Months Ended September 30, 2012
The net loss for the third quarter of 2012 was $0.8 million or $3.69 per share, compared with a net loss of $0.9 million or $7.13 per share for the third quarter of 2011. Working capital was $3.1 million as of September 30, 2012, compared with $4.6 million as of December 31, 2011. The Company's cash and cash equivalents as of September 30, 2012 were $3.7 million, compared with $4.9 million as of December 31, 2011. In November 2012, Spherix raised $2.6 million in a private placement.
The net loss for the nine months ended September 30, 2012 was $2.7 million or $13.31 per share, compared with a net loss of $2.2 million or $17.13 per share for the nine months ended September 30, 2011.
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis. Biospherics is exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of our products, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop products may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
Condensed Consolidated Statements of Operations
Three Months Ended Sept. 30,
Nine Months Ended Sept. 30,
Research and development expense
Selling, general and administrative expense
Total operating expenses
Loss from operations
Gain on settlement of obligations
Loss before taxes
Income tax expense
Net loss per share, basic
Net loss per share, diluted
Weighted average shares outstanding, basic
Weighted average shares outstanding, diluted
Condensed Consolidated Balance Sheets
Sept. 30, 2012
Cash and cash equivalents
Trade accounts receivable, net of allowance of $0 and $8,174
Prepaid research expenses
Prepaid expenses and other assets
Total current assets
Property and equipment, net of accumulated depreciation of $316,438 and $265,502
Patents, net of accumulated amortization of $0 and $2,146
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses
Accrued salaries and benefits
Total current liabilities
Commitments and contingencies
Preferred stock, $0.01 par value, 2,000,000 shares authorized; 5,250 series B issued and 1 outstanding at September 30, 2012 and December 31, 2011
Common stock, $0.01 par value, 2,500,000 shares authorized; 208,207 and 155,150 issued, 207,806 and 154,723 outstanding at September 30, 2012 and December 31, 2011, respectively